Correlation Between Stress, Anxiety, and Depression Related to COVID-19 Pandemic among Patients with Rheumatoid Arthritis and Non-compliance to Treatment: A Cross-Sectional Study

Baharak Tasorian 1, Mohsen Tabatabaei 2 and Mehran Shayganfard 3, *

1Internal Medicine Department, Arak University of Medical Sciences, Arak, Iran
2Office of Vice Chancellor for Research, Arak University of Medical Sciences, Arak, Iran
3Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran

*Corresponding author: Department of Psychiatry, Arak University of Medical Sciences, Arak, Iran. Email: mshayganfard@yahoo.com

Received 2021 July 16; Revised 2022 May 23; Accepted 2022 May 30.

Abstract

Background: The prevalence of anxiety and depression is high in rheumatoid arthritis (RA) patients. As RA patients tend to be immunodeficient, they are at greater risk of coronavirus disease 2019 (COVID-19) infection due to their scheduled hospital appointments. Therefore, they have become more anxious and worried during COVID-19 pandemic, and some patients recently have canceled or postponed their treatment.

Objectives: This study aimed to assess the effect of stress, anxiety, and depression due to COVID-19 outbreak on non-compliance to treatment among RA patients.

Methods: In this cross-sectional study, we included 149 RA patients (male/female = 12: 137). Four questionnaires, including the 21-item Depression, Anxiety, and Stress Scale (DASS-21), 14-item Perceived Stress Scale (PSS-14), 18-item Health Anxiety Inventory (HAI-18), and 8-item Morisky Medication Adherence Scale (MMAS-8) were employed. The questionnaires were filled by the researchers on behalf of the participants using telephone interviews due to social distancing protocol.

Results: There was a significant negative correlation between stress (P = 0.001), anxiety (P < 0.001), health anxiety (P = 0.014), and depression (P = 0.001) and compliance to treatment among RA patients. However, anxiety was the only predictor for non-compliance to treatment.

Conclusions: Therapists should be aware of the symptoms of stress, anxiety, and depression among their RA patients, especially during stressful life events, and carefully monitor their compliance to treatment to prevent exacerbation of RA.

Keywords: Rheumatoid Arthritis, COVID-19, Non-compliance

1. Background

Rheumatoid arthritis (RA), an immune-mediated arthropathy, is a chronic disease (1) which can cause pain and limit the movements of patients (2). Therefore, it can be debilitating and negatively affect the sufferer’s occupational functioning by disabling them in the climax of their career, especially in the fourth and fifth decades of life (1). Moreover, RA can increase the patient’s medical costs (2) and affect the sufferer’s educational functioning, social functioning, and received social support (2). As RA worsens the sufferer’s quality of life, it is highly associated with anxiety and depression (1-4). Depression, anxiety, and mixed anxiety-depressive disorder make the patients’ levels of pain perception, fatigue, disability, and disease activity increase, and their response to RA treatment worsens (1, 5, 6). Furthermore, depression leads to increased mortality in RA patients (7).

Certain cytokines [e.g., tumor necrosis factor α (TNFα) and interferon γ (IFNγ)] increase in the frontal cortex by serotonergic antidepressants. Some studies mentioned that anti-inflammatory drugs, the most commonly used RA medications, may attenuate the antidepressant effect of the serotonergic drugs by inhibiting this process (8). Some other studies showed that psychiatric medications may be associated with potentially adverse side effects or even lead to exacerbation of RA symptoms (1, 9, 10).

Based on a systematic analysis (11), RA prevalence and incidence rates are increasing by time, and this condition is challenging the public health globally. However, the early identification and treatment of RA, especially in females, can reduce its burden (11).
SARS-CoV-2 (severe acute respiratory coronavirus 2 syndrome) is a new viral infectious disease which originated from Wuhan in the Hubei province of China (12). Because of the rapid and global spread of the SARS-CoV-2, the World Health Organization (WHO) announced the disease as a public health emergency, calling it coronavirus disease 2019 (COVID-19) (13). COVID-19, in severe cases, may progress to interstitial pneumonia and alveolar damage, severe acute respiratory distress syndrome (ARDS), and even death (14). Studies showed that patients suffering from rheumatoid disease may be at higher risk of infection under certain conditions (15-17). The higher risk in RA patients is due to the following reasons: (1) RA itself can lead to dysregulation and premature aging of the immune system; (2) RA is associated with a variety of chronic comorbidities, such as diabetes, which aggravate this immunocompromising condition; and (3) the immunosuppressive antirheumatic drugs which are used to treat RA can significantly increase the risk of infection (e.g., glucocorticoids (GCs) increase the risk by up to 4-fold and TNF-α inhibitors increase the risk by up to 2-fold) (17). Although there is no evidence showing that the mentioned factors make the RA patients susceptible to COVID-19 infection, these people might be at higher risk of complications if infected (18).

Shayganfard et al. (19) showed that higher health anxiety scores during the COVID-19 pandemic resulted in canceling or postponing routine medical health care in women in the perinatal stage. Michaud et al. (20) also showed that RA patients appeared more anxious and frightened during COVID-19 pandemic and they postponed or canceled their medical appointments, and some even stopped their medications.

2. Objectives

This study aimed to assess the effect of stress, anxiety, health anxiety, and depression on non-compliance to treatment in patients suffering from RA during the current SARS-CoV-2 pandemic.

3. Methods

3.1. Study Design

This cross-sectional study was carried out in Arak, Iran, from 20 March to 20 April 2020. This period was the flare-up of COVID-19 in Arak. Because of the social distancing measures during the COVID-19 outbreak, the questionnaires were filled by the researchers, who made telephone calls to the participants and asked them the questions of the questionnaires. During the phone calls, the aim of the study and the entire process, including the time the participants may take to answer the questions, were explained.

The study protocol was approved by the local institutional ethics committee of Arak University of Medical Sciences, and all human procedures were performed in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments. Also, informed consent was taken verbally before recording the participants’ answers.

3.2. Patients

In this study, using the simple random sampling method, we included 149 patients who met the American College of Rheumatology (ACR) classification criteria for RA registered in the Iranian National Registry of rheumatic diseases (RHEUMATRY). These patients were registered by the Arak Rheumatology Registry Management Office (ARMO) in RHEUMATRY.

The inclusion criteria were patients over 18 years old suffering from RA for at least six months prior to the study, signing informed consent, being under immunosuppressive treatment such as prednisolone, and being treated as an outpatient. The exclusion criteria were request from the patient to leave the study at any stage of the study, RA exacerbation, change of patient status from outpatient to inpatient during the study, and infection with COVID-19.

3.3. Tools

In this study, the psychological effects of COVID-19 on RA patients (i.e., stress, anxiety, and depression) were assumed to be independent variables, and non-compliance to treatment was considered as the dependent variable. We collected the demographic information, including age, gender, education, marital status, and occupation, which could act as potential confounding factors or modifiers. Four questionnaires, including the 21-item Depression, Anxiety, and Stress Scale (DASS-21), 14-item Perceived Stress Scale (PSS-14), 18-item Health Anxiety Inventory (HAI-18), and 8-item Morisky Medication Adherence Scale (MMAS-8) were also employed.

3.3.1. The Depression, Anxiety, and Stress Scale (DASS)

This is a reliable screening tool for depression, anxiety, and stress experienced over the subject’s past week. The DASS has been designed based on the concept that depression, anxiety, and stress are all three dimensions of the same disorder which differ in severity (21). The scores obtained from each of the three subscales of DASS are categorized as ‘normal, mild, moderate, severe, and extremely severe’ based on their severity.
In this study, the short 21-item version of DASS was used, which has seven questions for each subscale. The longer version consists of 42 items. The DASS is a 4-point self-rated scale based on a Likert scale, which consists of the following items: 0 = did not apply to me at all; 1 = applied to me to some degree or sometimes; 2 = applied to me to a considerable degree; or a good part of time; 3 = applied to me very much, or most of the time (22). To acquire an equivalent score to the 42-item DASS, the results for each subscale were multiplied by 2. DASS is available in multiple languages, including Farsi (23). The Farsi version has been validated in several studies (24-26) and has an acceptable psychometrics and good internal consistency (Cronbach alpha for: total DASS-21 = 0.94; Depression = 0.85; Anxiety = 0.85; Stress = 0.87) (24).

3.3.3. The Perceived Stress Scale (PSS)

This scale is widely used to measure general stress of the participants in previous month and evaluate how stressful and/or controllable the respondents find a life situation or event. PSS is a self-rated scale which is scored based on a 5-point Likert scale comprising of: 0 = never; 1 = almost never; 2 = sometimes; 3 = fairly often; 4 = very often (30, 31). There are three versions of PSS available, which differ in their number of items (4, 10, or 14 items) (30, 31). In this study, the Farsi version with 14 items (PSS-14) was used. The Farsi version has an acceptable psychometrics and good internal consistency (overall Cronbach’s α coefficient of 0.76) (32).

3.3.4. The Morisky Medication Adherence Scale (MMAS)

This is a fast and easy-to-use self-reported instrument to evaluate the compliance of the patient to treatment (33, 34). In this study, the 8-item version (MMAS-8) was applied, which has a better validity and reliability than the 4-item version (MMAS-4) in (35). Seven items of MMAS-8 are scored based on dichotomous yes/no questions (for items 1-4 and 6-7: yes = 0, no = 1; for item 5: yes = 1, no = 0), and the last (8th) item uses a 5-item Likert scale comprising of: All the time = 0 to never/rarely = 4. The response (0 - 4) is divided by 4 to standardize the score of the last item (34). The total score of MMAS-8 ranges from 0 to 8 (35). A total score of 8 suggests high compliance; 5 or less, low compliance and between 5 and 8 (6 and 7), medium compliance (34). The MMAS-8 has been translated to the Farsi with an acceptable internal consistency (overall Cronbach’s α coefficient of 0.697), sensitivity (92.8%), specificity (22.3%), positive predictive value (52.9%), negative predictive value (76.7%), and reliable test-retest reproducibility (r = 0.940; p < 0.001) (36).

3.4. Statistical Analysis

The data was analyzed using SPSS v.20. The descriptive statistics were analyzed as a whole and based on gender. Then, the difference between the descriptive statistics of the two gender groups were analyzed using the t-test, independent samples test, and Levene’s test for equality of variances. To analyze the correlation between the variables, the Pearson and Spearman Rho’s correlation tests were used. Assuming the compliance to treatment as a dependent variable, the linear relationship between the independent variables and the MMAS was assessed using the analysis of variances (ANOVA) and multiple linear regression model (enter method).

4. Results

4.1. Demographic Data of Participants

As mentioned above, 149 RA patients participated in this study. The age range of participants was 21 - 76 years (mean age: 46 years) and male to female ratio was 12:137. Also, 135 (90.6%) patients were married, and 14 (9.4%) were single (no divorced, widowed, or separated). Regarding job status, two (1.3%) patients were unemployed, 41 (27.5%) were employed, and 106 (71.1%) were housewives. In addition, 50 (33.6%) participants had high school or lower education, 55 (36.9%) had a diploma, and 44 (29.5%) had university education.
4.2. Descriptive Statistics

In this study, four scales of PSS-14, DASS-21, HAI-18, and MMAS-8 were used. The mean and standard deviation of each scale are summarized in Table 1.

The severities (normal, mild, moderate, severe, and extremely severe) for each of the three subscales of DASS (stress, anxiety, and depression) are summarized in Table 2. The compliance to treatment was categorized as high, medium, and low. A summary of the frequencies of the compliance to treatment is illustrated in Table 2.

4.3. Correlations

The correlation between stress, anxiety, depression, illness likelihood, illness severity, body vigilance, and compliance to treatment is summarized in Table 3.

As illustrated in Table 3, there was a significant negative correlation between Compliance with treatment and the scores of PSS scale ($r = 0.006$, DASS total scores ($r = 0.001$), stress subscale scores of DASS ($r = 0.001$), anxiety subscale scores of DASS ($r < 0.001$), depression subscale scores of DASS ($r = 0.001$), HAI total scores ($r = 0.014$), and illness likelihood subscale scores of HAI ($r < 0.001$).

No statistically significant correlation was found between compliance to treatment and illness severity subscale scores of HAI and body vigilance subscale scores of HAI.

4.4. Regression Models

The linear relationship between the independent variables (age, gender, marital status, education, occupation, PSS total score, HAI total score, and DASS total score) and compliance to treatment was assessed using the multiple linear regression model (enter method). The ANOVA P-value for this regression model was 0.004 ($F = 2.976$, adjusted $R^2 = 0.097$). Among the independent variables, the only statistically significant P-value was for DASS total score ($r = 0.005$, $t = -3.240$, Betta = -0.327). The P-values for the other independent variables were not statistically significant (age’s $r = 0.311$, education’s $r = 0.167$, occupation’s $r = 0.560$, marital status’ $r = 0.219$, PSS total $r = 0.951$, HAI total $r = 0.980$). Therefore, we used the regression model only for the DASS total score (as an independent variable) and the MMAS total score (as a dependent variable) by the Enter method. The ANOVA for this regression model was statistically significant ($P < 0.001$, $F = 19.207$, adjusted $R^2 = 0.097$, $t = -3.838$, Betta = -0.340). To find a more precise relationship between DASS and MMAS results, the regression model was used again while considering the DASS subscales (stress, anxiety, and depression) as independent variables. The ANOVA for the model was statistically significant ($P-value < 0.001$, $F = 7.417$, adjusted $R^2 = 0.115$). Anxiety was the only subscale which had a statistically significant relationship with compliance to treatment ($P = 0.006$, $t = -2.796$, Betta = -0.284). The P-values for the other two subscales were not significant (stress’ $P = 0.513$, depression’s $P = 0.633$).

5. Discussion

In this study, a negative significant correlation was found between stress, anxiety, and depression and compliance to treatment (Table 3). The higher stress, anxiety, and depression symptoms in RA patients are likely due to less compliance in treatment and vice versa. However, this does not necessarily mean that as the stress, anxiety, and depression of the patients increase, they adhere less to treatment. The multiple linear regression model showed that the only predictor for non-compliance to treatment was anxiety. In other words, as RA patients become more anxious, they become less likely to adhere to their treatment. Greater risk of COVID-19 infection in older people with multiple health comorbidities who receive immunosuppressive drugs (37, 38) in combination with increased risk of COVID-19 cross-infection during hospital visits (16, 20) increase the patients’ anxiety during the COVID-19 pandemic. This may negatively affect compliance to treatment in RA patients. Michaud et al. (20) found that during the COVID-19 pandemic, 42% of rheumatologic patients had a degree of change in their care, including cancellation or postponement of their appointments or even changes to their medications by their own decision. Shayanfard et al. (19) also showed that higher health anxiety scores during the COVID-19 pandemic resulted in cancelling or postponing the routine medical health care in women in the perinatal stage. As illustrated in Table 3, there was a negative correlation between compliance to treatment and health anxiety (HAI-18) and between compliance to treatment and illness likelihood scores in RA patients. Hence, the more anxious RA patients are as a result of their health being threatened and the possibility of having a serious illness, the less they adhere to their treatment.

Based on the existing literature, this is the first study conducted on health anxiety in RA patients. However, our study had some limitations. First, for more reliable results, we asked the participants to focus on COVID-19 while answering the HAI questionnaire. However, RA patients suf-
Table 1. The Mean and Standard Deviation for Stress, Anxiety, Health Anxiety, Depression, and Compliance to Treatment

| Variables | PSS-14 | DASS-21 | HAI-18 | MMAS-8 |
|-----------|--------|---------|--------|--------|
|           | Total  | Stress  | Anxiety | Depression | Total | Illness Likelihood | Illness Severity | Body Vigilance | MMAS-8 |
| Mean (N = 149) | 24.92 | 42.99 | 18.87 | 10.75 | 13.37 | 19.89 | 12.75 | 5.10 | 9.24 | 5.38 |
| Std. Deviation | 8.77 | 24.64 | 10.01 | 8.49 | 10.20 | 8.02 | 4.06 | 2.71 | 3.80 | 1.85 |

Abbreviations: PSS-14, the 14-item Perceived Stress Scale; DASS-21, the 21-item Depression, Anxiety and Stress Scale; HAI-18, the 18-item Health Anxiety Inventory; MMAS-8, the Morisky Medication Adherence Scale.

Table 2. The Frequency of the Severities

| Compliance to Treatment | DASS Stress | DASS Anxiety | DASS Depression |
|-------------------------|-------------|--------------|-----------------|
| Severity                | No. (%)     | Severity     | No. (%)         | Severity     | No. (%)         | Severity     | No. (%) |
| Low                     | 82 (55)     | Normal       | 52 (34.9)       | Normal       | 62 (41.6)       | Normal       | 59 (39.6) |
|                         |             | Mild         | 23 (15.4)       | Mild         | 12 (8.1)        | Mild         | 23 (15.4) |
| Medium                  | 54 (36.2)   | Moderate     | 34 (22.8)       | Moderate     | 30 (20.1)       | Moderate     | 33 (22.1) |
|                         |             | Severe       | 25 (16.8)       | Severe       | 22 (14.8)       | Severe       | 18 (12.1) |
| High                    | 13 (8.7)    | Extremely Severe | 15 (10.1) | Extremely Severe | 23 (15.4) | Extremely Severe | 16 (10.7) |

Abbreviation: DASS, Depression, Anxiety and Stress Scale.

Table 3. The Correlation Between Stress, Anxiety, Depression, Illness Likelihood, Illness Severity and Body Vigilance and Compliance to Treatment.

| Compliance to Treatment | PSS-14 | DASS-21 | HAI-18 |
|-------------------------|--------|---------|--------|
|                          | Total  | Stress  | Anxiety | Depression | Total  | Illness Likelihood | Illness Severity | Body Vigilance | MMAS-8 |
| Correlation Coefficient | -0.215 | -0.340 | -0.390 | -0.250 | -0.166 | -0.201 | -0.191 | -0.087 | -0.155 | -0.096 | 0.088 | -0.038 |
| P (2-tailed)             | 0.005  | < 0.001 | 0.004 | 0.012 | < 0.001 | 0.003 | 0.077 | 0.046 | < 0.001 | 0.318 | 0.058 | 0.430 | 0.286 | 0.495 |

Abbreviations: PSS-14, the 14-item Perceived Stress Scale; DASS-21, the 21-item Depression, Anxiety and Stress Scale; HAI-18, the 18-item Health Anxiety Inventory.

Shiraz E-Med J. 2022; 23(9):e117966.
5.1. Conclusions

Future cohort studies should focus on compliance to treatment of RA patients and compare the patients who are in stressful life events with those who are not. In conclusion, depression is a predictor of non-compliance to treatment (44) and therapists should be aware of the early signs and symptoms of depression in their rheumatologic patients. However, the therapists should also look for symptoms of stress and anxiety in their patients and monitor their compliance to treatment during stressful life events to prevent further exacerbation of RA.

Acknowledgments

The authors would like to express their sincere gratitude to Pouya Kamali, dental student at Cardiff University, for copy editing the manuscript.

Footnotes

Authors’ Contribution: Study concept and design, M. S. and B. T.; Collecting the clinical data, B. T. and M. T.; Analysis and interpretation of data, M. S. and M. T.; Drafting of the manuscript, B. T. and M. S.; Critical revision of the manuscript for important intellectual content, M. S., B. T. and M. T.; Final approval of the published version, M. S., B. T. and M. T.; Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved, M. S., B. T. and M. T.

Conflict of Interests: The authors declare no conflict of interests.

Data Reproducibility: It was not declared by the authors.

Ethical Approval: IR.ARAKMU.REC.1398.338 (ethics.research.ac.ir/EthicsProposalViewEn.php?id=125755).

Funding/Support: This study was supported by Arak University of Medical Sciences [grant number: IR.ARAKMU.REC.1398.338].

Informed Consent: An informed consent was obtained verbally before the questions of the questionnaires were asked from the participants.

References

1. Fiest KM, Hitchon CA, Bernstein CN, Peschken CA, Walker JR, Graff IA, et al. Systematic Review and Meta-analysis of Interventions for Depression and Anxiety in Persons With Rheumatoid Arthritis. J Clin Rheumatol. 2017;23(8):345–34. doi: 10.1097/RHU.0000000000000489. [PubMed: 2822131]. [PubMed Central: PMC570477].

2. VanDyke MM, Parker JC, Smarr KL, Hewett JE, Johnson GE, Slaughter JR, et al. Anxiety in rheumatoid arthritis. Arthritis Rheum. 2004;51(3):408–12. doi: 10.1002/art.20474. [PubMed: 15188326].

3. Lok EF, Mok CC, Cheng CW, Cheung EF. Prevalence and determinants of psychiatric disorders in patients with rheumatoid arthritis. Psychosomatics. 2010;51(4):338–338 e8. doi: 10.1017/appsi.51.4.338. [PubMed: 20587762].

4. Isik A, Koca SS, Ozturk A, Mermi O. Anxiety and depression in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(6):3872–3878. doi: 10.1007/s10067-006-0407-9. [PubMed: 1694197].

5. Mok CC, Lok PY, Cheung EF. Concurrent psychiatric disorders are associated with significantly poorer quality of life in patients with rheumatoid arthritis. Scand J Rheumatol. 2012;41(4):253–9. doi: 10.3109/03009742.2012.664648. [PubMed: 2285761].

6. Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos G. Comorbidity in patients with rheumatoid arthritis: effect on health-related quality of life. J Rheumatol. 2004;31(1):58–65. [PubMed: 1470529].

7. van den Hoek J, Boshuizen HC, Roorda LD, Tijhuis GJ, Nurmohamed MT, Dekker J, et al. Association of Somatic Comorbidities and Comorbidity With Mortality in Patients With Rheumatoid Arthritis: A 14-Year Prospective Cohort Study. Arthritis Care Res (Hoboken). 2016;68(8):1055–60. doi: 10.1002/acr.22881. [PubMed: 26663143].

8. Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A. 2011;108(22):9262–7. doi: 10.1073/pnas.1014836108. [PubMed: 2158864]. [PubMed Central: PMC307316].

9. Peretti S, Judge R, Hindmarsh I. Safety and tolerability considerations: tricyclic antidepressants vs. selective serotonin reuptake inhibitors, Acta Psychiatr Scand Suppl. 2000;403:17–25. doi: 10.1111/j.1600-0477.2000.tb09444.x. [PubMed: 10109931].

10. Ferguson M. SSRI Antidepressant Medications: Adverse Effects and Tolerability. Prim Care Companion J Clin Psychiatry. 2003;5(1):22–7. doi: 10.4088/pcc.v05n1005. [PubMed: 1540625]. [PubMed Central: PMC18155].

11. Safiri S, Kolahi AA, Hoy D, Smith E, Bettampadi D, Mansournia MA, et al. Global, regional and national burden of rheumatoid arthritis 1990–2017: a systematic analysis of the Global Burden of Disease study 2017. Ann Rheum Dis. 2019;78(10):1463–7. doi: 10.1136/annrheumdis-2019-259290. [PubMed: 3150227].

12. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–3. doi: 10.1038/s41586-020-2027-7. [PubMed: 3205557]. [PubMed Central: PMC7095148].

13. Favalli E, Ingegnoli F, De Lucia O, Cincinelli G, Gimaz R, Caporalli R. COVID-19 infection and rheumatoid arthritis: Faraway, so close!. Autoimmun Rev. 2020;19(5):202523. doi: 10.1016/j.autrev.2020.102523. [PubMed: 3220516]. [PubMed Central: PMC70259].

14. Yang X, Yu Y, Yu J., Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81. doi: 10.1016/S2213-2600(20)30079-5. [PubMed: 3205612]. [PubMed Central: PMC710525].

15. Figueroa-Parra G, Aguirre-Garcia GM, Gamboa-Alonso CM, Camacho-Ortiz A, Galarza-Delgado DA. Are my patients with rheumatic diseases at higher risk of COVID-19? Ann Rheum Dis. 2020;79(1):389–40. doi: 10.1136/annrheumdis-2020-271322. [PubMed: 3205516].

16. Zhang Y, Wang J, Zhao J, Xiao Z. Online management of rheumatoid arthritis during COVID-19 pandemic. Ann Rheum Dis. 2021;80(1). doi: 10.1136/annrheumdis-2020-271348. [PubMed: 3234097].

17. Listing J, Gerhold K, Zink A. The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford). 2013;52(1):53–61. doi: 10.1093/rheumatology/kes305. [PubMed: 2319291].

18. Roongta R, Ghosh A. Managing rheumatoid arthritis during COVID-19. Clin Rheumatol. 2020;39(1):237–44. doi: 10.1007/s10067-020-05358-2. [PubMed: 3289251]. [PubMed Central: PMC474575].
32. Safaei M, Shokri O. Assessing Stress in Cancer Patients: Factorial Validity of the Perceived Stress Scale in Iran. Iranian Journal of Psychiatric Nursing. 2014;2(2):133–22. Persian.

33. Morisisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):167-74. doi: 10.1097/00005185-198601000-00007. [PubMed: 3945109].

34. De Las Cuevas C, Penate W. Psychometric properties of the eight-item Morisky Medication Adherence Scale (MMAS-8) in a psychiatric outpatient setting. Int J Clin Health Psychol. 2015;5(2):321-9. doi: 10.1016/j.ijchp.2014.11.003. [PubMed: 30487829]. [PubMed Central: PMC624788].

35. Kubica A, Kosobucka A, Michalski P, Fabiszek T, Felsmann M. Self-reported questionnaires for assessment adherence to treatment in patients with cardiovascular diseases. Med Res. 2012;4:315-22.

36. Moharazad Y, Saadat H, Nakhhavan Shahrazi B, Rai A, Saadat Z, Aerab-Shiabani H, et al. Validation of the Persian Version of the 8-item Morisky Medication Adherence Scale (MMAS-8) in Iranian Hypertensive Patients. Glob Heart. 2015;7(1):73-83. doi: 10.5539/ghs.v7n1p73. [PubMed: 25946926]. [PubMed Central: PMC4802120].

37. Liu J, Cao R, Xu M, Wang X, Zhang H, Hu H, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16. doi: 10.1038/s41421-020-0156-6. [PubMed: 32994961]. [PubMed Central: PMC7078228].

38. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol. 2020;38(2):775-80. doi: 10.55563/cinerheumatol/c38916. [PubMed: 32207680].

39. Heidari P, Cross W, Weller C, Nazarinia M, Crawford K. Medication adherence and related cost and treatment non-adherence in patients with rheumatoid arthritis: A cross-sectional study. Int J Rheum Dis. 2019;22(4):555-66. doi: 10.1111/1600-0462.13949. [PubMed: 30924299].

40. Salt F, Frazier SK. Predictors of Medication Adherence in Patients with Rheumatoid Arthritis. Drug Dev Res. 2011;72(3):575-63. doi: 10.1002/ddr.20484. [PubMed: 22267889]. [PubMed Central: PMC3216531].

41. Bak-Sosnowska M, Wyszomirska J, Daniel-Sielanczyk A. Selected psychological factors and medication adherence in patients with rheumatoid arthritis. Reumatologia. 2021;59(2):90-7. doi: 10.5144/reumat.2021.105431. [PubMed: 33976462]. [PubMed Central: PMC8103406].

42. Oshohtes C, Zullig LL, Bosworth HB, Tu P, Lin C. Self-Efficacy and Adherence Behaviors in Rheumatoid Arthritis Patients. Prev Chronic Dis. 2018;15:E27. doi: 10.5888/pcd15.180218. [PubMed: 30339772]. [PubMed Central: PMC6198676].

43. Joplin S, van der Zwan R, Joshua F, Wong PK. Medication adherence in patients with rheumatoid arthritis: the effect of patient education, health literacy, and musculoskeletal ultrasound. Biomed Res Int. 2015;2015:350658. doi: 10.1155/2015/350658. [PubMed: 26060812]. [PubMed Central: PMC4427825].

44. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455-61. doi: 10.1001/jama.288.4.455. [PubMed: 12123975].

45. Sampaio R, Azevedo LF, Dias CC, Castro Lopes JM. Non-Adherence to Pharmacotherapy: A Prospective Multicentre Study About Its Incidence and Its Causes Perceived by Chronic Pain Patients. Patient Prefer Adherence. 2020;14:321-32. doi: 10.2147/PPA.S232577. [PubMed: 32109998]. [PubMed Central: PMC7037084].

46. Broekmans S, Dobbels F, Milisen K, Morlion B, Vanderschueren-Walenkamp AME. Predictors of adherence to exercise interventions during and after cancer treatment: A systematic review. Psychooncology. 2018;27(3):773-24. doi: 10.1002/pon.4612. [PubMed: 29247584]. [PubMed Central: PMC5887924].